Search Results

Engineered B Cell Medicine Gets Orphan Drug Status for Hemophilia

• Authors : Park, Brian

• Source: MPR Monthly Prescribing Reference. June 5, 2024

Record details

FDA Approves Companion Diagnostic for Hemophilia B Gene Therapy Beqvez

• Authors : Park, Brian

• Source: MPR Monthly Prescribing Reference. April 30, 2024

Record details

Beqvez Approved as One-Time Gene Therapy for Hemophilia

• Authors : Park, Brian

• Source: MPR Monthly Prescribing Reference. April 27, 2024

Record details

FDA approves Alhemo injection as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B with inhibitors.

• Source: PR Newswire. 2024.

Record details

CSL Behring receives approval in Canada for hemophilia B

• Source: R & D Focus Drug News. October 27, 2023

Record details

FDA Grants Orphan Drug Designation for BE-101, a Novel Engineered B Cell Medicine, for the Treatment of Hemophilia B.

• Source: Plus Company Updates. 2024.

Record details

U.S. FDA Approves Pfizer's BEQVEZtm, a One-Time Gene Therapy for Adults with Hemophilia B.

• Source: Plus Company Updates. 2024.

Record details

Researcher from Ruhr-University Bochum Reports on Findings in HIV/AIDS (Biological Barriers for Drug Delivery and Development of Innovative Therapeutic Approaches in HIV, Pancreatic Cancer, and Hemophilia A/B)

• Source: AIDS Vaccine Week. September 30, 2024, 23

Record details

Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials

• Authors : Astermark, Jan; Wojciechowski, Piotr; Aballea, Samuel

• Source: Journal of Blood Medicine. July 31, 2021, Vol. 12, p613, 9 p.

Record details

Fidanacogene Elaparvovec, a Gene Therapy for Hemophilia B, Under Review

• Authors : Park, Brian

• Source: MPR Monthly Prescribing Reference. June 28, 2023

Record details